Over- and underdiagnosis of prostate cancer: The dangers

European Urology, Supplements

Volumn 5, Issue 6, 2006, Pages 511-513

  Tombal, Bertrand ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Diagnosis; Prostate cancer; PSA; Screening; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER PREVENTION; CANCER SCREENING; CONFERENCE PAPER; GENE OVEREXPRESSION; HUMAN; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; URINALYSIS;

EID: 33644852170     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.02.019     Document Type: Conference Paper

References (13)

1. T.A. Stamey, N. Yang, and A.R. Hay Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 1987 909 916
2. W.J. Catalona, D.S. Smith, and T.L. Ratliff Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening JAMA 270 1993 948 954
3. A. Bill-Axelson, L. Holmberg, and M. Ruutu Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 352 2005 1977 1984
4. Rocco B, de Cobelli O, Leon ME, et al. Sensitivity and Detection Rate of A 12-Core Trans-Perineal Prostate Biopsy: Preliminary Report. Eur Urol 2006, in press, doi:10.1016/j.eururo.2005.12.021.
5. J.C. Medd, M.R. Stockler, and R. Collins Measuring men's opinions of prostate needle biopsy ANZ J Surg 75 2005 662 664
6. P.C. Albertsen, J.A. Hanley, and J. Fine 20-year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095 2101
7. M. McGregor, J.A. Hanley, and J.F. Boivin Screening for prostate cancer: estimating the magnitude of overdetection CMAJ 159 1998 1368 1372
8. R. Postma, M. Roobol, and F.H. Schroder Lesions predictive for prostate cancer in a screened population: first and second screening round findings Prostate 61 2004 260 266
9. I.M. Thompson, D.K. Pauler, and P.J. Goodman Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per millilitre N Engl J Med 350 2004 2239 2246
10. A.W. Roddam, M.J. Duffy, and F.C. Hamdy Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis Eur Urol 48 2005 386 399
11. M.J. Roobol, R. Kranse, and H.J. de Koning Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM) Urology 63 2004 309 313
12. D. Hessels, J.M. Klein Gunnewiek, and I. van Oort DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer Eur Urol 44 2003 8 16
13. M.P. van Gils, U.H. Stenman, and J.A. Schalken Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project Eur Urol 48 2005 1031 1041